eEnzyme, LLC & Healthgen Biotechnology


Healthgen Biotechnology Corp. (Healthgen Biotech), specializing in molecular pharmaceutical research and development, is focusing on developing and manufacturing a series of animal-free and safety products by using the state-of-the Art platform called OryzHiExp, having high capacity to express proteins or small peptides in the rice grain.
Utilizing the rice endosperm cell specific expression platform, Healthgen Biotech have achievements in developing and commercializing a series of products, including recombinant human serum albumin (OsrHSA), recombinant human basic fibroblast growth factor (OsrbFGF), recombinant alphar-1 antitrypsin (OsrAAT), recombinant human epidermal growth factor (OsrEGF), recombinant human basic fibroblast growth factor (OsrbFGF), recombinant human Fibronectin (OsrFn), recombinant human lactoferrin (OsrLF), and recombinant lysozyme (OsrLYZ). Meanwhile, based on the OryzHiExp expression platform, Healthgen Biotech can provide customized protein or peptides expression services.
The recombinant human serum albumin (OsrHSA) has gained the DMF from US FDA, which number is 029648. The OsrHSA can be used as excipient and stabilizer in a variety of pharmaceutical preparations and serum-free cell culture medium component.
Healthgen Biotech’s Quality Control System has been certified by ISO 9001: 2008 and ensures standardized process as well as qualified produc

The World Advanced Therapies and Regenerative Medicine Congress and Exhibition is an international conference and exhibition featuring the latest in advanced therapies, bioengineering and surrounding technology. To attend the conference which features global leaders in the biopharma and regenerative medicine industries, there is a registration fee. The exhibition is free to visit.

Register your pass here.